

## **Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer's disease**

Egan MF, Mukai Y, Voss T, Kost J, Stone J, Furtek C, Mahoney E, Cummings JL, Tariot PN, Aisen PS, Vellas B, Lines C, Michelson D.

Alzheimer's research and therapy

2019; 11(1):e68

### **ARTICLE IDENTIFIERS**

DOI: 10.1186/s13195-019-0520-1

PMID: 31387606

PMCID: PMC6685277

### **JOURNAL IDENTIFIERS**

LCCN: 2009243541

pISSN: not available

eISSN: 1758-9193

OCLC ID: 427406256

CONS ID: not available

US National Library of Medicine ID: 101511643

This article was identified from a query of the SafetyLit database.